Coave Therapeutics

The Coave team will be presenting two oral and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held 11-15 May 2026 in Boston, including groundbreaking data on our OneAAV™ universal capsid. OneAAV™ decouples tissue targeting from capsid design and serotype selection, meaning that targeting is driven by externally conjugated ligands. Adrien Savy will present exciting pre-clinical data that shows how this approach addresses key challenges associated with systemic gene therapy delivery, enabling precise tissue targeting, unprecedented liver de-targeting, and immune evasion. Our second oral presentation (presented by Julien SPATAZZA) and two poster presentations (presented by Brahim Belbellaa and Lavaniya Kunalingam) will further showcase the potential of our ligand-conjugation technology to enhance vectors for targeted gene therapy. If you are attending, please reach out and connect. Read the full press release here: https://lnkd.in/eDx3_VR4 #ASGCT2026 #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

The Coave team will be presenting two posters at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place 3–7 May in Denver, Colorado, USA. At the meeting, Lolita Petit, CSO will present preclinical data from our first-in-class ligand-conjugated suprachoroidal AAV vector, coAAV-SCS, while Brahim Belbellaa, Senior Director, Preclinical Ophthalmology will present on our lead gene therapy program for wet AMD and other retinal vascular diseases, CoTx-101. We look forward to engaging with fellow researchers, clinicians, and industry leaders at one of the key global gatherings in ophthalmology. Read the full press release here: https://lnkd.in/eB-A7RyR #ARVO26 #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

Our CEO Rodolphe Clerval will be presenting at Eyecelerator, held alongside the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, on 1 May in Denver, CO. Eyecelerator @ ARVO features a full day of KOL-driven presentations and networking, highlighting industry advancements and innovative new products disrupting eye care. Rodolphe will share Coave’s vision for gene therapy in ophthalmology, including how our first-in-class ligand-conjugated AAVs are helping advance novel targeted approaches for retinal vascular diseases, including through our lead program CoTx-101. We look forward to joining fellow leaders and innovators at one of the standout events in the ophthalmology calendar. Register for the event here:  https://lnkd.in/eHJSzPqF #ARVO26 #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

Our CEO Rodolphe Clerval will be presenting at the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mediterranean on Wednesday 29 April in Rome. Rodolphe will highlight how Coave Therapeutics is redefining targeted gene therapy through its first-in-class, ligand-conjugated AAVs, designed to enable precise delivery and durable efficacy for the treatment of retinal vascular diseases. Register for the event here: https://lnkd.in/dathw_2 #CGMediterranean #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

We’re excited to introduce a new monthly series from Coave Therapeutics: Precision, Delivered. In this series, we will take a closer look at gene therapy, its promise, its potential, and the fundamental challenge that has constrained its broader impact: delivery. Gene therapy was designed to address disease at its genetic root, offering the potential for durable, effective and safe treatments across a broad spectrum of disease. In ophthalmology, this promise is particularly compelling. The eye’s immune-privileged environment and accessibility make it an attractive setting for innovative genetic medicines. And yet, despite scientific progress, gene therapy has largely remained confined to a minority of rare diseases. Why? Because delivery has been the limiting factor. Traditional AAV-based approaches rely on genetic engineering of vectors to achieve tissue targeting. This strategy presents important constraints in ophthalmology: ·      Limited tissue specificity and off-target exposure ·      Immune responses that can restrict re-administration and second-eye treatment ·      Invasive routes of administration, including subretinal surgery ·      Trade-offs between durability, efficacy and safety Coave is focused on solving these challenges without trade-offs, with our lead program CoTx-101. Powered by the world’s first ligand-conjugated AAVs, our Precision Vectors are designed to decouple manufacturing from targeting, enabling modular, scalable, and highly tissue-specific delivery of gene therapies. We look forward to advancing the conversation in this rapidly evolving field and sharing more with the next installment of Precision, Delivered. #PrecisionDelivered #Ophthalmology #GeneTherapy #RetinalVascularDiseases #WetAMD #DME #AAVVectors #TargetedGeneTherapy #Biotech

#ICYMI Last week, our colleagues Marie-Anne Burlot and Ludmila JURICEK presented two posters at the AAV Vectors Workshop in Paris, organised by the SFTCG-French Society for Cell and Gene Therapy. Marie-Anne and Ludmila shared insights from our pioneering work using the world's first ligand-conjugated AAVs, for both suprachoroidal and systemic delivery. A huge thank you to the organisers for putting together such an engaging event and to everyone who stopped by to discuss our mission to redefine targeted gene therapy. #SFTCG #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

Our CEO Rodolphe Clerval will be participating in the RBC Capital Markets Virtual Ophthalmology Conference on Tuesday 24 March. Rodolphe will join Lisa A. Walter, PhD, VP Biotech Equity Research at RBC, for a fireside chat to discuss how Coave’s first-in-class, ligand-conjugated AAVs are redefining targeted gene therapy for the treatment of retinal vascular diseases. Register for the event here: https://lnkd.in/e--UqXFt #RBC #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

Our colleagues Marie-Anne Burlot and Ludmila JURICEK are presenting two posters today at the AAV Vectors Workshop in Paris, organised by the SFTCG-French Society for Cell and Gene Therapy. Marie-Anne and Ludmila will be sharing insights from our work with the world’s first ligand-conjugated AAVs, using both suprachoroidal and systemic delivery. We’re looking forward to engaging with the scientific community and discussing our progress towards redefining targeted gene therapy. If you’re attending the workshop, we’d be delighted to connect. #SFTCG #Ophthalmology #GeneTherapy #PrecisionVectors #AAV #Innovation

We’re excited to share that our CEO Rodolphe Clerval was recently featured on The BioHub Podcast with Max Brennan, MSc.   During their engaging conversation, they discussed:   -Rodolphe’s unconventional journey from biochemical engineering to investment banking, equity research, business development and ultimately to CEO of Coave Therapeutics -How Coave Therapeutics is improving treatment for retinal vascular diseases such as wet AMD, through its proprietary ligand conjugated AAV vectors to solve the problem of delivery in targeted gene therapy -How Coave’s lead program aims to combine the durability of gene therapy with the efficacy and safety of biologics Listen to the full episode here: https://lnkd.in/eN5vZXwj #Ophthalmology #RetinalVascularDiseases #WetAMD #GeneTherapy #TargetedGeneTherapy #AAVVectors #Innovation

February is Age-related Macular Degeneration (AMD) and Low Vision Awareness Month. AMD is one of the leading causes of vision loss among older adults worldwide, with approximately 200 million people affected globally – a number expected to rise significantly as populations age. At Coave Therapeutics, we're committed to advancing targeted gene therapies for retinal vascular diseases such as wet AMD, with the goal of improving outcomes by delivering durable vision gains via an in-office procedure. For more information on wet AMD, visit the American Macular Degeneration Foundation:  https://lnkd.in/edSUiWTw #AMDAwarenessMonth2026 #Ophthalmology #RetinalVascularDiseases #WetAMD #GeneTherapy #TargetedGeneTherapy